Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

December 21, 2023

https://www.globenewswire.com/news-release/2023/12/21/2799882/11974/en/Pluri-and-Bar-Ilan-University-to-Develop-PLX-Cells-for-the-Treatment-of-Cocaine-Addiction.html

HAIFA, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) — Pluri Inc. (Nasdaq:PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote well-being and sustainability, announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University. Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Read more at globenewswire.com

Related news for (PLUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.